Reported 1 day ago
BeOne Medicines Ltd. (ONC), previously known as BeiGene, has received approval from the European Commission for its drug Tevimbra (tislelizumab), which targets multiple types of cancer, including small cell lung cancer and nasopharyngeal carcinoma. This approval signifies a key step in the company's expansion within the European biotech landscape, driven by its strategic rebranding and growth in research and development. BeOne has also made notable progress in hematology treatments and plans to accelerate its pipeline with new clinical trials.
Source: YAHOO